Biochemical markers of bone metabolism: an overview.

[1]  L. B. Scheiber,et al.  Evaluation and treatment of postmenopausal osteoporosis. , 1998, Seminars in arthritis and rheumatism.

[2]  D. Bauer,et al.  Biochemical markers of bone turnover in osteoporosis , 2013, Marcus and Feldman's Osteoporosis.

[3]  C. Langman,et al.  Five osteocalcin assays compared: tracer specificity, fragment interference, and calibration. , 1997, Clinical chemistry.

[4]  C Marcelli,et al.  Markers of bone resorption predict hip fracture in elderly women: The EPIDOS prospective study , 1996, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[5]  C. Christiansen,et al.  Evaluation of a new commercial IRMA for bone-specific alkaline phosphatase during treatment with hormone replacement therapy and calcitonin. , 1996, Clinical chemistry.

[6]  B. Clarke,et al.  Osteoporosis: Etiology, diagnosis, and management, 2nd ed Edited by B. Lawrence Riggs, M.D. and L. Joseph Melton, M.D., III. Philadelphia, Lippincott-Raven Publishers, 1995, $125.00 (xv + 542 pages), ISBN 0-7817-0275-5 , 1996, Trends in Endocrinology & Metabolism.

[7]  W. Dmowski,et al.  Urinary N‐Telopeptides to Monitor Bone Resorption While on GnRH Agonist Therapy , 1996, Obstetrics and gynecology.

[8]  W. Murphy,et al.  Comparative study of alendronate versus etidronate for the treatment of Paget's disease of bone. , 1996, The Journal of clinical endocrinology and metabolism.

[9]  P. Delmas,et al.  Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis , 1996, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[10]  M. Plebani,et al.  New and traditional serum markers of bone metabolism in the detection of skeletal metastases. , 1996, Clinical biochemistry.

[11]  P. Geusens,et al.  Oral alendronate induces progressive increases in bone mass of the spine, hip, and total body over 3 years in postmenopausal women with osteoporosis. , 1996, Bone.

[12]  J Dequeker,et al.  Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. , 1995, The New England journal of medicine.

[13]  Rees,et al.  Monoclonal antibody assay for measuring bone-specific alkaline phosphatase activity in serum. , 1995, Clinical chemistry.

[14]  N. Hanania,et al.  Dose-related decrease in bone density among asthmatic patients treated with inhaled corticosteroids. , 1995, The Journal of allergy and clinical immunology.

[15]  V. Chinchilli,et al.  Biochemical markers of bone turnover in patients with metastatic bone disease. , 1995, Clinical chemistry.

[16]  H. Genant,et al.  Alendronate treatment of the postmenopausal osteoporotic woman: effect of multiple dosages on bone mass and bone remodeling. , 1995, The American journal of medicine.

[17]  S. Wimalawansa.  Combined therapy with estrogen and etidronate has an additive effect on bone mineral density in the hip and vertebrae: four-year randomized study. , 1995, The American journal of medicine.

[18]  C. Christiansen,et al.  Different effects of bisphosphonate and estrogen therapy on free and peptide‐bound bone cross‐links excretion , 1995, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[19]  P. Delmas,et al.  Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. , 1994, The Journal of clinical endocrinology and metabolism.

[20]  S. Adami,et al.  Long‐term effects of a treatment course with oral alendronate of postmenopausal osteoporosis , 1994, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[21]  P. Delmas,et al.  Assessment of bone resorption with a new marker of collagen degradation in patients with metabolic bone disease. , 1994, The Journal of clinical endocrinology and metabolism.

[22]  P. Delmas,et al.  Characteristics of a two-site immunoradiometric assay for human skeletal alkaline phosphatase in serum. , 1994, Clinical chemistry.

[23]  P. Delmas,et al.  Markers of bone turnover in hyperthyroidism and the effects of treatment. , 1994, The Journal of clinical endocrinology and metabolism.

[24]  P. Delmas,et al.  Characterization of immunoreactive forms of human osteocalcin generated in vivo and in vitro , 1994, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[25]  H. Genant,et al.  Monitoring bone resorption in early postmenopausal women by an immunoassay for cross‐linked collagen peptides in urine , 1994, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[26]  P. Dombernowsky,et al.  Interpretation of results for tumor markers on the basis of analytical imprecision and biological variation. , 1993, Clinical chemistry.

[27]  J. Risteli,et al.  Biochemical markers of bone metabolism. , 1993, Annals of medicine.

[28]  P. Woo,et al.  Biochemical prediction of changes in spinal bone mass in juvenile chronic (or rheumatoid) arthritis treated with glucocorticoids. , 1993, The Journal of rheumatology.

[29]  A. Ratcliffe,et al.  Urinary hydroxypyridinium crosslinks of collagen as markers of bone resorption and estrogen efficacy in postmenopausal osteoporosis , 1993, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[30]  P. Fottrell,et al.  Sandwich enzyme immunoassay of osteocalcin in serum with use of an antibody against human osteocalcin. , 1993, Clinical chemistry.

[31]  H. Rosen,et al.  Immunoassay for urinary pyridinoline: The new marker of bone resorption , 1993, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[32]  J. Risteli,et al.  Radioimmunoassay for the pyridinoline cross-linked carboxy-terminal telopeptide of type I collagen: a new serum marker of bone collagen degradation. , 1993, Clinical chemistry.

[33]  L. Mosekilde,et al.  Serum markers of type I collagen formation and degradation in metabolic bone disease: Correlation with bone histomorphometry , 1993, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[34]  D. Perrett,et al.  Assay of pyridinium crosslinks in serum using narrow-bore ion-paired reversed-phase high-performance liquid chromatography. , 1993, Journal of chromatography.

[35]  B. Riggs,et al.  Utility of type I procollagen propeptide assays for assessing abnormalities in metabolic bone diseases , 1992, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[36]  D. Eyre,et al.  A specific immunoassay for monitoring human bone resorption: Quantitation of type I collagen cross‐linked N‐telopeptides in urine , 1992, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[37]  J. Bilezikian,et al.  Urinary pyridinium crosslinks of collagen Specific markers of bone resorption in metabolic bone disease , 1992, Trends in Endocrinology & Metabolism.

[38]  P. Virkkunen,et al.  Serum concentration of the cross-linked carboxyterminal telopeptide of type I collagen (ICTP) is a useful prognostic indicator in multiple myeloma. , 1992, British Journal of Cancer.

[39]  H. Fleisch.  Bisphosphonates , 2012, Drugs.

[40]  L. Mosekilde,et al.  Effects of a combined estrogen‐gestagen regimen on serum levels of the carboxy‐terminal propeptide of human type I procollagen in osteoporosis , 1991, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[41]  P. Delmas,et al.  Biochemical markers of bone turnover: methodology and clinical use in osteoporosis. , 1991, The American journal of medicine.

[42]  M. Prummel,et al.  Bone-alkaline phosphatase as indicator of bone formation. , 1991, Clinica chimica acta; international journal of clinical chemistry.

[43]  C. Christiansen,et al.  Urinary excretion of pyridinoline crosslinks correlates with bone turnover measured on iliac crest biopsy in patients with vertebral osteoporosis , 1991, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[44]  D. Reid,et al.  Evaluation of urinary hydroxypyridinium crosslink measurements as resorption markers in metabolic bone diseases , 1991, European journal of clinical investigation.

[45]  C. Christiansen,et al.  Effect of menopause and hormone replacement therapy on the urinary excretion of pyridinium cross-links. , 1991, The Journal of clinical endocrinology and metabolism.

[46]  A. Fujimori,et al.  Nongenomic activation of the calcium message system by vitamin D metabolites in osteoblast-like cells. , 1990, Endocrinology.

[47]  B. Smedsrød,et al.  Circulating C-terminal propeptide of type I procollagen is cleared mainly via the mannose receptor in liver endothelial cells. , 1990, The Biochemical journal.

[48]  G. Stein,et al.  Gene expression during endochondral bone development: Evidence for coordinate expression of transforming growth factor β1 and collagen type I , 1990, Journal of cellular biochemistry.

[49]  K. Lau,et al.  Development of an immunoassay for human serum osteoclastic tartrate-resistant acid phosphatase. , 1990, The Journal of clinical endocrinology and metabolism.

[50]  J. Risteli,et al.  Radioimmunoassay of the carboxyterminal propeptide of human type I procollagen. , 1990, Clinical chemistry.

[51]  K. Mann,et al.  Comparison of monoclonal and polyclonal antibody‐based immunoassays for osteocalcin: A study of sources of variation in assay results , 1990, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[52]  G. Rodan,et al.  Direct effects of 17 beta-estradiol on trabecular bone in ovariectomized rats. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[53]  M. Kleerekoper,et al.  Urinary total hydroxyproline measured by HPLC: comparison of spot and timed urine collections. , 1990, Clinical chemistry.

[54]  R. Wolfert,et al.  The preparation of monoclonal antibodies which react preferentially with human bone alkaline phosphatase and not liver alkaline phosphatase. , 1990, Clinica chimica acta; international journal of clinical chemistry.

[55]  T. Martin,et al.  Bone cell physiology. , 1989, Endocrinology and metabolism clinics of North America.

[56]  P. Fottrell,et al.  Solid-phase enzymoimmunoassay for osteocalcin in human serum or plasma, with use of a monoclonal antibody. , 1989, Clinical chemistry.

[57]  E. Canalis,et al.  Parathyroid hormone enhances the transcript and polypeptide levels of insulin-like growth factor I in osteoblast-enriched cultures from fetal rat bone. , 1989, Endocrinology.

[58]  S. Epstein.  Serum and urinary markers of bone remodeling: assessment of bone turnover. , 1988, Endocrine reviews.

[59]  K. Mann,et al.  Bone formation rate in older normal women: concurrent assessment with bone histomorphometry, calcium kinetics, and biochemical markers. , 1988, The Journal of clinical endocrinology and metabolism.

[60]  V. Maes,et al.  HPLC method for assay of bamifylline in plasma from neonates. , 1988, Clinical chemistry.

[61]  K. Mann,et al.  Concurrent assays of circulating bone Gla-protein and bone alkaline phosphatase: effects of sex, age, and metabolic bone disease. , 1988, The Journal of clinical endocrinology and metabolism.

[62]  D. Williams,et al.  Isolation and characterization of insulin-like growth factor-II from human bone. , 1988, Biochemical and biophysical research communications.

[63]  S. Robins,et al.  Quantitative analysis of the pyridinium crosslinks of collagen in urine using ion-paired reversed-phase high-performance liquid chromatography. , 1988, Analytical biochemistry.

[64]  S. Krane,et al.  Procollagen type I carboxy‐terminal extension peptide in serum as a marker of collagen biosynthesis in bone. Correlation with iliac bone formation rates and comparison with total alkaline phosphatase , 1987, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[65]  J. Kanis,et al.  Long-term follow-up observations on treatment in Paget's disease of bone. , 1987, Clinical orthopaedics and related research.

[66]  R. Bataille,et al.  Serum bone gla‐protein in multiple myeloma , 1987, Cancer.

[67]  J. Massagué,et al.  Human platelet-derived transforming growth factor-beta stimulates parameters of bone growth in fetal rat calvariae. , 1986, Endocrinology.

[68]  J. Fiddes,et al.  Human basic fibroblast growth factor: nucleotide sequence and genomic organization. , 1986, The EMBO journal.

[69]  R. Weinstein,et al.  Multiple immunoreactive forms of osteocalcin in uremic serum. , 1986, The Journal of clinical investigation.

[70]  L. Mosekilde,et al.  Estimation of bone turnover evaluated by 47Ca-kinetics. Efficiency of serum bone gamma-carboxyglutamic acid-containing protein, serum alkaline phosphatase, and urinary hydroxyproline excretion. , 1985, The Journal of clinical investigation.

[71]  J. Brosnan,et al.  Hydroxyproline metabolism by the rat kidney: distribution of renal enzymes of hydroxyproline catabolism and renal conversion of hydroxyproline to glycine and serine. , 1985, Metabolism: clinical and experimental.

[72]  A. Y. Foo,et al.  Two new methods for separating and quantifying bone and liver alkaline phosphatase isoenzymes in plasma. , 1984, Clinical chemistry.

[73]  P. Delmas,et al.  SERUM BONE GLA-PROTEIN: A SPECIFIC MARKER FOR BONE FORMATION IN POSTMENOPAUSAL OSTEOPOROSIS , 1984, The Lancet.

[74]  W. Nelp,et al.  Long-term calcitonin therapy in postmenopausal osteoporosis. , 1984, Metabolism: clinical and experimental.

[75]  T. Koob,et al.  Quantitation of hydroxypyridinium crosslinks in collagen by high-performance liquid chromatography. , 1984, Analytical biochemistry.

[76]  K. Mann,et al.  Effect of renal function on plasma levels of bone Gla-protein. , 1983, The Journal of clinical endocrinology and metabolism.

[77]  J. Stepan,et al.  Relationship of plasma tartrate resistant acid phosphatase to the bone isoenzyme of serum alkaline phosphatase in hyperparathyroidism. , 1983, Clinica chimica acta; international journal of clinical chemistry.

[78]  G. Siest,et al.  Total bone and liver alkaline phosphatases in plasma: biological variations and reference limits. , 1983, Clinical chemistry.

[79]  E. Canalis.  Effect of glucocorticoids on type I collagen synthesis, alkaline phosphatase activity, and deoxyribonucleic acid content in cultured rat calvariae. , 1983, Endocrinology.

[80]  L. Avioli.  Calcitonin therapy for bone disease and hypercalcemia. , 1982, Archives of internal medicine.

[81]  D. Moss.  Alkaline phosphatase isoenzymes. , 1982, Clinical chemistry.

[82]  Riggs Bl.  AN OVERVIEW OF OSTEOPOROSIS , 1982, The Lancet.

[83]  P. Price,et al.  Origin of the vitamin K-dependent bone protein found in plasma and its clearance by kidney and bone. , 1981, The Journal of biological chemistry.

[84]  E. Canalis.  Effect of platelet-derived growth factor on DNA and protein synthesis in cultured rat calvaria. , 1981, Metabolism: clinical and experimental.

[85]  D Fujimoto,et al.  The structure of pyridinoline, a collagen crosslink. , 1978, Biochemical and biophysical research communications.

[86]  M. Jayson,et al.  Collagen in Health and Disease , 1978, The Lancet.

[87]  C. Sherr,et al.  Radioimmunoassay for Human Procollagen , 1974, Science.

[88]  L. Demers.  Clinical usefulness of markers of bone degradation and formation. , 1997, Scandinavian journal of clinical and laboratory investigation. Supplementum.

[89]  R. Bouillon,et al.  Measurement of vitamin D and its metabolites (calcidiol and calcitriol) and their clinical significance. , 1997, Scandinavian journal of clinical and laboratory investigation. Supplementum.

[90]  M. Kleerekoper,et al.  Biochemical studies in the evaluation and management of osteoporosis: current status and future prospects. , 1996, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[91]  C. Burtis.  Tietz textbook of Clinical Chemistry , 1994 .

[92]  B. Riggs,et al.  Preventive effects of transdermal 17 beta-estradiol on osteoporotic changes after surgical menopause: a two-year placebo-controlled trial. , 1993, American journal of obstetrics and gynecology.

[93]  T. Tammela,et al.  Evaluation of the effect of oral clodronate on skeletal metastases with type 1 collagen metabolites. A controlled trial of the Finnish Prostate Cancer Group. , 1993, European journal of cancer.

[94]  B. Teisner,et al.  Quantification of fetal antigen 2 (FA2) in supernatants of cultured osteoblasts, normal human serum, and serum from patients with chronic renal failure. , 1992, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[95]  P. Fottrell,et al.  Osteocalcin: diagnostic methods and clinical applications. , 1991, Critical reviews in clinical laboratory sciences.

[96]  E. Canalis,et al.  Role of Insulin-Like Growth Factor I And II on Skeletal Remodeling , 1989 .

[97]  T. Kupper,et al.  Parathyroid hormone and lipopolysaccharide induce murine osteoblast-like cells to secrete a cytokine indistinguishable from granulocyte-macrophage colony-stimulating factor. , 1989, The Journal of clinical investigation.

[98]  M. Kleerekoper,et al.  Clinical Disorders of Bone and Mineral Metabolism , 1988 .

[99]  J. Stepan,et al.  Bone loss and biochemical indices of bone remodeling in surgically induced postmenopausal women. , 1987, Bone.

[100]  E. Canalis,et al.  Effects of endothelial cell growth factor on bone remodelling in vitro. , 1987, The Journal of clinical investigation.

[101]  L. Raisz,et al.  Stimulation of bone formation by prostaglandin E2. , 1984, Prostaglandins.

[102]  L. Kaplan,et al.  Clinical Chemistry: Theory, Analysis, and Correlation , 1984 .